Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Goebeler, M.-E., Knop, S., Viardot, A., Kufer, P., Topp, M. S., Einsele, H., Noppeney, R., Hess, G., Kallert, S., Mackensen, A., Rupertus, K., Kanz, L., Libicher, M., Nagorsen, D., Zugmaier, G., KlingLanguage:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.2014.59.1586
Date:
February, 2016
File:
PDF, 896 KB
english, 2016